MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

T2Candida Panel (2015 Prix Galien USA Winner)

    Arrow  backT2Candida T2Dx

T2Candida Panel (2015 Prix Galien USA Winner)

T2 Biosystems (Lexington, MA) touts its T2Candida Panel as the only FDA-cleared test for sepsis that does not require a blood culture that could potentially take days to produce a result. Instead, the T2Candida Panel is able to identify the five clinically relevant species of Candida within 4.5 hours. The company's  T2Dx Instrument uses proprietary T2 Magnetic Resonance technology to measures how water molecules react in the presence of magnetic fields.

The groundbreaking nature of the technology is getting attention. As of June 30, 41 customers including multiple hospital systems had committed to adopt the T2Dx Instrument at U.S. and European sites, according to the company. Revenue for the first six months of 2016 was $2.1 million, about triple what it was a year before, and Canon U.S.A. this month spent $40 million to buy nearly a fifth of T2 Biosystems's stock. 

Continue >>

[Image courtesy of T2 Biosystems]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.